Global Pemphigus Vulgaris Market, By Type (Pemphigus Vulgaris, others), By Diagnostic (Endoscopy, Skin Peeling, and Others) By End User (Biological Therapies, Corticosteroid, and Others) opportunities and forecast 2020-2027
Pemphigus is autoimmune disorder. It is group of the rare skin disorders which cause sores, blisters on skin, in mouth, or on genitals. In pemphigus the immune system incorrectly produces the antibodies that can kill healthy cells in skin and mucous membrane. Occasionally it may occur as a side effect of the medication by consuming the drugs of certain blood pressure.
Several factors are expected to drive growth of the market such as growing incidence of cancer, consumption of the tobacco, the unhealthy lifestyle, growing pollution, growing geriatric population and the rising awareness for oral hygiene. According to international pemphigus & the pemphigoid foundation, about 2,500 people in U.S. were suffering from the pemphigus disorder. The worldwide incidences of the pemphigus were 40,000 to 50,000 in 2017.Segment Overview
Increasing awareness about diseases such as influenza, better health care infrastructure, technological advancements, augmented R&D expenditure, augmented investment by the major players for development of the treatment, increase in the government initiatives and rich product pipeline, are major drivers of global pemphigus vulgaris market. However, high cost of the drug development and Regional Overview
Geographically, the North America is expected to dominate global pemphigus market. The market growth in the region is accredited to increasing geriatric population suffering from the pemphigus disorder, investment in the research and development and the technological advancement. According to U.S. National Institute of Health almost 32 cases per million of the population population were reported for the pemphigus in the US.
Europe is anticipated to be second largest market in globe owing to increasing number of the geriatric populations, growing government expenditure for the oral hygiene, rising disposable income and growing use of tobacco in the region. According to data by Europe PMC, in 2017, occurrences of the pemphigus ranging from the 0.5 cases per million of the population in the Germany to almost 8 cases per million of the population in Greece.
Asia-Pacific is expected to be fastest growing market owed to growing prevalence of the pemphigus, and the oral related problems in developing countries, growing disposable income and the growing healthcare expenditure.
The Middle East and Africa is anticipated to account for lowest market share in tglobal pemphigus market owing to lack of technical knowledge, the low development, and the poor medical facilities in these developing economies.Competitor overview
Major players operating in global pemphigus market include Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Alexion, Vifor Pharma Management Ltd., argenx, Genentech, Inc., and Principia Biopharma.Key Players
- Novartis Pharmaceuticals,
- Hoffmann-La Roche,
- Principia Biopharma, Inc,
- Argenx, Sanofi S.A.,
- Pfizer Inc.,
- Teligent Inc,
- GlaxoSmithKline LLC,
- Teva Pharmaceutical Industries
- Pemphigus Vulgaris
- Pemphigus Foliaceus
- Pemphigus Vegetans
- Paraneoplastic Pemphigus
- Skin peeling
- Run blood tests
- Skin biopsy
By End User
- Academic and Research Institutes
- Hospitals and Clinics
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA